Watson Barred From Generic Actos Market; Mylan, Teva, Ranbaxy May Enter First
This article was originally published in PharmAsia News
Watson sues FDA, challenging the agency’s decision not to approve its ANDA for generic Actos while granting market exclusivity to other ANDA filers. The company planned to launch Aug. 17.
You may also be interested in...
Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.